579 related articles for article (PubMed ID: 19949016)
1. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
J Clin Oncol; 2010 Jan; 28(2):340-7. PubMed ID: 19949016
[TBL] [Abstract][Full Text] [Related]
2. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation.
Galvão DA; Taaffe DR; Spry N; Joseph D; Turner D; Newton RU
Prostate Cancer Prostatic Dis; 2009; 12(2):198-203. PubMed ID: 18852703
[TBL] [Abstract][Full Text] [Related]
3. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer.
Segal RJ; Reid RD; Courneya KS; Malone SC; Parliament MB; Scott CG; Venner PM; Quinney HA; Jones LW; D'Angelo ME; Wells GA
J Clin Oncol; 2003 May; 21(9):1653-9. PubMed ID: 12721238
[TBL] [Abstract][Full Text] [Related]
4. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer.
Segal RJ; Reid RD; Courneya KS; Sigal RJ; Kenny GP; Prud'Homme DG; Malone SC; Wells GA; Scott CG; Slovinec D'Angelo ME
J Clin Oncol; 2009 Jan; 27(3):344-51. PubMed ID: 19064985
[TBL] [Abstract][Full Text] [Related]
6. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
7. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
[TBL] [Abstract][Full Text] [Related]
8. Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.
Galvão DA; Taaffe DR; Spry N; Newton RU
Prostate Cancer Prostatic Dis; 2007; 10(4):340-6. PubMed ID: 17486110
[TBL] [Abstract][Full Text] [Related]
9. Effects of aerobic or aerobic and resistance training on cardiorespiratory and skeletal muscle function in heart failure: a randomized controlled pilot trial.
Mandic S; Tymchak W; Kim D; Daub B; Quinney HA; Taylor D; Al-Kurtass S; Haykowsky MJ
Clin Rehabil; 2009 Mar; 23(3):207-16. PubMed ID: 19218296
[TBL] [Abstract][Full Text] [Related]
10. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.
Hansen PA; Dechet CB; Porucznik CA; LaStayo PC
PM R; 2009 Nov; 1(11):1019-24. PubMed ID: 19942188
[TBL] [Abstract][Full Text] [Related]
11. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial.
Courneya KS; Segal RJ; Mackey JR; Gelmon K; Reid RD; Friedenreich CM; Ladha AB; Proulx C; Vallance JK; Lane K; Yasui Y; McKenzie DC
J Clin Oncol; 2007 Oct; 25(28):4396-404. PubMed ID: 17785708
[TBL] [Abstract][Full Text] [Related]
12. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR.
Galvão DA; Spry N; Denham J; Taaffe DR; Cormie P; Joseph D; Lamb DS; Chambers SK; Newton RU
Eur Urol; 2014 May; 65(5):856-64. PubMed ID: 24113319
[TBL] [Abstract][Full Text] [Related]
13. Moderators of the effects of exercise training in breast cancer patients receiving chemotherapy: a randomized controlled trial.
Courneya KS; McKenzie DC; Mackey JR; Gelmon K; Reid RD; Friedenreich CM; Ladha AB; Proulx C; Vallance JK; Lane K; Yasui Y; Segal RJ
Cancer; 2008 Apr; 112(8):1845-53. PubMed ID: 18306372
[TBL] [Abstract][Full Text] [Related]
14. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial.
Green HJ; Pakenham KI; Headley BC; Yaxley J; Nicol DL; Mactaggart PN; Swanson CE; Watson RB; Gardiner RA
BJU Int; 2004 May; 93(7):975-9. PubMed ID: 15142146
[TBL] [Abstract][Full Text] [Related]
15. Mediators of the resistance and aerobic exercise intervention effect on physical and general health in men undergoing androgen deprivation therapy for prostate cancer.
Buffart LM; Galvão DA; Chinapaw MJ; Brug J; Taaffe DR; Spry N; Joseph D; Newton RU
Cancer; 2014 Jan; 120(2):294-301. PubMed ID: 24122296
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Pummer K; Lehnert M; Stettner H; Hubmer G
Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
[TBL] [Abstract][Full Text] [Related]
17. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.
Taaffe DR; Newton RU; Spry N; Joseph D; Chambers SK; Gardiner RA; Wall BA; Cormie P; Bolam KA; Galvão DA
Eur Urol; 2017 Aug; 72(2):293-299. PubMed ID: 28249801
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer.
Ott C; Fulton MK
J Am Acad Nurse Pract; 2005 Mar; 17(3):113-22. PubMed ID: 15748224
[TBL] [Abstract][Full Text] [Related]
19. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
Pether M; Goldenberg SL; Bhagirath K; Gleave M
Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
[TBL] [Abstract][Full Text] [Related]
20. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
